加替沙星治疗呼吸道及尿路感染的随机对照试验

目的 评价加替沙星葡萄糖注射液静脉及口服片剂序贯给药治疗下呼吸道感染及尿路感染的疗效与安全性。方法试验组先以加替沙星注射剂静脉给药,继以加替沙星片剂口服；对照组先以左氧氟沙星注射剂静脉给药，继以左氧氟沙星片剂口服。对2种药治疗社区获得性肺炎、慢性支气管炎急性发作期、急性肾盂肾炎、复杂性尿路感染及反复发作性尿路感染的疗效和安全性进行随机对照试验。结果 加替沙星组和左氧氟沙星组临床有效率分别为87．5％与85．7％：痊愈率分别为75．0％与64．3％；细菌清除率分别为92．3％与88．9％，不良反应发生率分别为11．1％和3．4％；实验室检查异常发生率分别为22．7％和4．2％，以上结果经统计学处理差异均无显著意义。结论 本研究结果显示，加替沙星注射剂静脉给药用于全身症状明显的社区获得性肺炎、急性肾盂肾炎等感染的初期治疗可使病情早期缓解，继以口服完成疗程，可获良好疗效；疗效与安全性均与左氧氟沙星相仿。

Randomized control trial of gatifloxacin treatment in respiratory and urinary tract infection

Objective: To investigate the efficacy and safety of gatifloxacin gluose solution and tablets treatment of lower respiratory and urine tract infection through vein firstly, then orally. Methods: Trial group used gatifloxcin solution through vein, then gatifloxcin tablets; control group used levofloxacin solution through vein, then levofloxacin tablets. A random control trial was done to investigate the efficacy and safety of the two drugs treatment of the community acquired pneumonia. Chronic bronchitis with acute bacteria infection acute pyelonephritis complicated and recurrent urine tract infection. Results: The availability rates of gatifloxacin and levofloxacin group were 87. 5% and 85. 7% , curability rate were 75. 0% and 64. 3% respectively, bacteria elimination rates of the two groups were 92. 3% and 88. 9% respectively, side effect rates of the two groups were 11. 1% and 3. 4%, and the rates of abnormal results from laboratory were 22. 7% and 4. 2% respectively. No remarkable difference all of above. Conclusions: Gatifloxacin solutions can relieve diseases earlier when treating community acquired pyelonephritis with obvious systematic syndromes in early stage, then giving tablets, after finishing the whole stages, we can get good curative effect; levofloxacin solutions and tabelts have the same efficacy and safety.